title: SGLT2 versus DPP4 inhibitors for type 2 diabetes.
authors.affiliation: Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, Department of Medicine, CHU Sart Tilman, B-4000 Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be.
authors.forename: André J
authors.initials: AJ
authors.lastname: Scheen
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D011719:Pyrazines; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D014230:Triazoles; C570240:empagliflozin; D000068900:Sitagliptin Phosphate